Tipranavir: A new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 6, 2007, Pages 839-850

  de Mendoza, Carmen ^a   Morelló, Judit ^a   Garcia Gascó, Pilar ^a   Rodríguez Novoa, Sonia ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Drug resistance; Protease inhibitors; Tipranavir

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PLUS RITONAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LIVER ENZYME; LOPERAMIDE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE;

ABNORMAL LABORATORY RESULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CODON; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; FATIGUE; GENE MUTATION; GENETIC CODE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MUTATIONAL ANALYSIS; NAUSEA; NONHUMAN; PHENOTYPE; PRESCRIPTION; SIDE EFFECT; VIRUS LOAD; VIRUS STRAIN; VOMITING; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; TREATMENT OUTCOME; VIROLOGY;

CLINICAL TRIALS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-2; HUMANS; MUTATION; PYRIDINES; PYRONES; RITONAVIR; TREATMENT OUTCOME;

EID: 34247863946     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.6.839     Document Type: Article

References (63)

1. PALELLA F, DELANEY K, MOORMAN A et al.: Declining morbidity and mortality in an ambulatory HIV-infected population. N. Engl. J. Med. (1998) 338:853-860.
2. DETELS R, TARWATER P, PHAIR J et al.: Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infection before and after AIDS diagnosis. AIDS (2001) 15:347-355.
3. LEDERBERGER B, EGGER M, OPRAVIL M et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patient: a prospective cohort study. Swiss HIV cohort study. Lancet (1999) 353:863-868.
4. DE MENDOZA C, GARRIDO C, CORRAL A et al.: Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res. Hum. Retroviruses In press.
5. SAX P: FDA approval: tipranavir. AIDS. Clin. Care (2005) 17:78.
6. RUSCONI S, LA SETA CATAMNCIO S, CITTERIO P et al.: Susceptibility to PNU-140690 (Tipranavir) of HIV-1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents. Chemother. (2000) 44:1328-1332.
7. MEHANDRU S, MARKOWITZ M: Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. Expert. Opin. Investig. Drugs (2003) 12:1821-1828.
8. KING J, ACOSTA E: Tipranavic a novel non-peptidic protease inhibitor of HIV. Clin. Pharmocokinetics (2006) 45:665-682.
9. POPPE S, SLADE D, CHONG K et al.: Antiviral activity of the dihydropyrone PNU-140690, a new non-peptidic HIV protease inhibitor. Antimicrob. Agents. Chemother. (1997) 41:1058-1063.
10. BACK N, VAN WIJK A, REMMERSWAAL D et al.: In-vitro susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS (2000) 14:101-102.
11. YENI P: Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J. Acquir. Immune. Defic. Syndr. (2003) 34:S91-S94.
12. CROOM K, KEAM S: Tipranavir: a ritonavir-boosted protease inhibitor. Drugs (2005) 65:1669-1677.
13. Aptivus (tipranavir), Capsules, 250 mg. Packet insert. Product information guide, 2006. Boehringer-Ingelheim.
14. WANG Y, DAENZER C, WOOD R et al.: The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor in Phase II study in antiretroviral naïve HIV-infected patients. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (4 - 8 February 2000) Abstr. 673.
15. HAMMER S, SAAG M, SCHECHTER M et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 296:827-843.
16. LAZZARIN A, FEINBERG J, KRAFT M et al.: Week 48 efficacy of TPV/r treatment is enhanced in patients with higher numbers of genotypically available background drugs in RESIST 1 and 2. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (12 - 16 November 2006) Abstr. P24.
17. COOPER D, ZAJDENVERG R, RUXRUNGTHAN K et al.: Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naïve patients. Results of BI 1182.33. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (12- 16 November 2006) Abstr. PL13.4.
18. SLATER L, FARTHING C, JAYAWEERA J et al.: Safety and efficacy of tipranavir (TPV) a non-peptidic protease inhibitor in PI-failure patients (BI 1182.4). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (16- 19 December 2001) Abstr. LB-15.
19. GATHE J, PIERONE G, PILIERO P et al.: Efficacy and safety of three doses of tipranvir boosted with ritonavir in treatment-experienced HIV-1 infected patients. AIDS Res. Hum. Retroviruses (2007).
20. GATHE J, COOPER D, FARTHING C et al.: Efficacy of the protease inhibitor tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin. Infect. Dis. (2006) 43:1337-1346.
21. CAHN P VILLACIAN J, LAZZARIN A et al.: Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin. Infect. Dis. (2006) 43:1347-1356.
22. HICKS C, CAHN P, COOPER D et al.: Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1 infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet (2006) 368:466-475.
23. WALMSLEY S, HALL D, SHERER J et al.: Better treatment response (TR) to tipranavir/r (TPV/r) compared to lopinavir/r (LPV/r) in patients with higher LPV mutation scores. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (12 - 16 November 2006) Abstr. P197.
24. HOEN B, TOWNER W, OPRAVIL M et al.: The Aptivus compassionate use program (CUP): safety and efficacy data from 3,920 patients in the clinic. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (12 - 16 November 2006) Abstr. P162.
25. SARACINO A, SUTER F, DI PERRI G et al.: Genotypic resistance to tipranavir/ritonavir (TPV/r) in the Italian EAP BI 1182.16 study. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (12 - 16 November 2006) Abstr. P210.
26. DE MENDOZA C, VALER L, RIBERA E et al.: Performance of six different ritonavir-boosted protease inhibitors-based regimens in heavily antiretroviral-experienced HIV-infected patients. HIV. Clin. Trials (2006) 7:163-171.
27. GALLEGO O, DE MENDOZA C, CORRAL A et al.: Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitor-experienced patients: implications for tipranavir use. AIDS Patient Care STDs (2005) 19:67-69.
28. RACE E, DAM E, OBRY V et al.: Analysis of HIV cross-resistance to PI using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS. (1999) 13:2061-2068.
29. SCHAPIRO J, WINTERS M, LAWRENCE J et al.: Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS. (1999) 13:359-365.
30. LARDER B, HERTOGS K, BLOOR S et al.: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS (2000) 14:1943-1948.
31. DOYON L, TREMBLAY S, BOURGON L et al.: Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res (2005) 68:27-35.
32. BAXTER J, SCHAPIRO J, BOUCHER C et al.: Genotypic changes in HIV-1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. (2006) 80:10794-10801.
33. NAEGER L, STRUBLE K: Food and drug administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS (2007) 21:179-185.
34. COAKLEY E, CHAPPEY C, FLANDRE P et al.: Defining lower (L) and upper (U) phenotypic clinical cutoffs (CCO's) For tipranavir/r (TPV/r), lopinavir/r (LPV/r), saquinavir/r (SQV/r) and amprenavir/r (APV/r) within the RESIST data set by the PhenoSense assay. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (27 - 30 September 2006) Abstr. H-995.
35. KOHLBRENNER M, HALL B, BAXTER D et al.: Limited cross-resistance to tipranavir in patients previously created with two or more protease inhibitors. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (12-16 November 2006) Abstr. P209.
36. MARCELIN AG, MASQUELIER B, DESCAMPS D et al.: Mutations associated with response to boosted tipranavir in HIV-1 infected protease inhibitor-experienced patients. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA (25 - 28 February 2007) Abstr. 612.
37. TURNER S, STROHBACH J, TOMMASI R et al.: Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6 dihydro-4-hydroxy-2pyrone sulphonamide class. J. Med. Chem. (1998) 41:3467-3476.
38. ELSTON R, SCHERER J, HALL D et al.: De-selection of the I50V mutation occurs in clinical isolates during aptivus/r (tipranavir/ ritonavir) based therapy. Antivir. Ther. (2006) 11:S102.
39. DE MENDOZA C, VALER L, BACHELER L et al.: Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS (2006) 20:1071-1074.
40. PARKIN N, CHAPPEY C, PETROPOULOS C: Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS (2003) 17:955-961.
41. JOHNSON V, BRUN-VEZINET F, CLOTET B et al.: Update of the drug resistance mutations in HIV-1: Fall 2006. Top. HIV. Med. (2006) 14:125-130.
42. VERGNE L, PEETERS M, MPOUDI-NGOLE E et al.: Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B HIV-1 strains: evidence of many minor drug resistance mutations in treatment naïve patients. J. Clin. Microbiol. (2000) 38:3919-3925.
43. VERGNE L, STUYVER L, VAN HOUTTE M et al.: Natural polymorphisms in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment naïve patients. J. Clin. Virol. (2006) 36:43-49.
44. PARREIRA R, MONTEIRO F, PADUA E et al.: Natural polymorphisms of HIV Type 2 pot sequences from drug-naive individuals. AIDS. Res. Hum. Retroviruses. (2006) 22:1178-1182.
45. RODES B, SHELDON J, TORO C et al.: Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J. Antimicrob. Chemother. (2006) 57:709-713.
46. FLEURY H, RECORDON-PISON P, CAUMONT A et al.: HIV-1 diversity in France, 1999-2001: molecular characterization of non-B HIV-1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS. Res. Hum. Retroviruses (2003) 19:41-47.
47. HOLGUIN A, SUNE C, HAMY F et al.: Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J. Clin. Virol. (2006) 36:264-271.
48. COLSON P, HENRY M, TOURRES C et al.: Polymorphism and drug-selected mutations in the protease gene of HIV-2 from patients living in Southern France. J. Clin. Microbiol (2004) 42:570-577.
49. POVEDA E, BARREIRO P, RODES B, SORIANO V: Enfuvirtide is actve aginst HIV Type 1 group O. AIDS Res. Hum. Retroviruses (2005) 21:583-585.
50. NTEMGWA M, BRENNER B, OLIVEIRA M et al.: Natural polymorphisms in the HIV-2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents. Chemother. (2007) 51:606-610.
51. GALLANT J: Protease inhibitor boosting in the treatment-experienced patient. AIDS Rev. (2004) 6:226-233.
52. SCOTT J: Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients. Am. J. Health. Syst. Pharm. (2005) 62:809-815.
53. D'AVOLIO A, SCIANDRA M, SICCARDI M et al.: A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. J. Chromatogr. (In Press)
54. NAEGER L, ZHENG J, STRUBLE K: Virologic Response to TPV based on plasma concentration and Baseline Resistance Parameters. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (5 - 8 February 2006) Abstr. 639.
55. BONORA S, GONZALEZ DE REQUENA D, CALAGNO A et al.: Tipranavir genotypic inhibitory quotient predicts early virological response to TPV-based salvage regimens. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (5 - 8 February 2006) Abstr. 577.
56. GARCIA-GASCO P, GARCIA J, POVEDA E et al.: Safety of tipranavir in heavily anriretroviral experienced HIV-infected patients with and without chronic hepatitis B/C. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (12 - 16 November 2006) Abstr. P112.
57. JULG B, BOGNER J, GORBRL F: Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: a case report. AIDS (2006) 20:1563.
58. RODRIGUEZ-NOVOA S, BARREIRO P, JIMENEZ-NACHER I et al.: Pharmacogenetics in HIV therapy. AIDS Rev. (2005) 7:103-112.
59. RODRIGUEZ-NOVOA S, MARTIN-CARBONERO L, BARREIRO P et al.: Genetic factors influencing arazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS (2007) 21:41-46.
60. BOFFITO M, MAITLAND D, POZNIAK AJ: Practical perspective of the use of tipranavir in combination with other medications: lessons learned from pharmacokinetics studies. Clin. Pharmacol. (2006) 46:130-139.
61. DONG B, COCOCHOBA J: Tipranavir: a protease inhibitor for HIV salvage therapy. Ann. Pharmacother. (2006) 40:1311-1321.
62. GONZALEZ DE, REQUENA D, CALCAGNO A et al.: Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS (2006) 20:1977-1979.
63. MORELLO J, RODRIGUEZ-NOVOA S, JIMENEZ-NACHER I et al.: Drug interactions for ripranavir, a new protease inhibitor. Drug. Metabolism. (2007) 1:81-84.